The Food and Drug Administration (FDA) on Wednesday issued an emergency use authorization for Novavax’s protein-based COVID-19 vaccine.
“Authorizing an additional COVID-19 vaccine expands the available vaccine options for the prevention of COVID-19, including the most severe outcomes that can occur such as hospitalization and death,” FDA Commissioner Robert Califf said in a statement.
The agency said the vaccine, under the emergency use authorization, can be given to adults aged 18 and older. The vaccine, which is given in two doses several weeks apart, can become available once the U.S. Centers for Disease Control and Prevention signs off on the FDA’s authorization….